GW Virtual Investor Event
Please join GW Pharmaceuticals for a review of the U.S. developement program and market opportunity for our late stage pipeline product, Nabiximols.
Nabiximols is expected to enter pivotal Phase 3 development in the United States in the second half of 2020. The U.S. commercial rights are owned by GW. GW anticipates developing multiple indications for nabiximols with an initial focus on spasticity. The initial target indication in the U.S. will be for the treatment of MS spasticity, potentially to be followed by Spinal Cord Injury spasticity and Post Traumatic Stress Disorder, or PTSD.
Nabiximols is a complex botanical medicine formulated from extracts of the cannabis plant that contains the principal cannabinoids THC and CBD and also contains minor constituents, including other cannabinoid and non-cannabinoid plant components, such as terpenes, sterols, and triglycerides. The product is administered as a mouth spray.
Nabiximols is known as Sativex® outside of the United States and is licensed and commercially available for the treatment of MS spasticity in numerous countries. The efficacy of Sativex for MS spasticity has been demonstrated in multiple positive pivotal trials conducted in Europe1.
Please RSVP to GW@troutgroup.com